06/12/13 Last month, Angelina Jolie shocked the world with a New York Times piece regarding her decision to have a preventative double mastectomy. For women whose mothers, grandmothers, sisters, and even fathers and grandfathers, have been diagnosed with breast cancer, there is the immediate concern for their loved one. But once the initial shock subsides, a creeping worry starts to appear in the back of your mind that maybe you could also carry the gene. I’ve spoken before about the unknown that comes with a cancer diagnosis, but I think it’s time we consider the doubt that comes before a diagnosis. As Jolie explained, once her doctors told her of the 87 percent risk of breast cancer, she decided to take the proactive step and minimize the risk.
Angeline Jolie provided the world with a moment of truth that revealed the brevity and bravery that we experience in the face of cancer. It is natural for us to be afraid of the unknown and challenging for us to take a risk because of fear. But, imagine a time when the unknown is no longer risky because what awaits us is better than we could expect. Imagine that one day when we are faced with the possibility of cancer and instead of taking a risk, we can know a treatment method is available that will eradicate the disease without radiation that will leave permanent scars on our bodies. These risks and the unknown solidify that we are in need of “a better way.” For the person contemplating preventative treatments, how long do they have to wait?
15 months ago, the GenV (human-sized radiowave machine) was delivered to the Kanzius Labs and Dr. Steven Curley at M.D. Anderson Cancer Center in Houston, Texas. Since the arrival, the machine has been calibrated, validated and readied for large non-human subject studies. Beginning in February 2013, large non-human subjects have received weekly injections of cancer cells into their liver – creating a consistent model in a “controlled environment.” This month, the subjects will undergo an MRI to determine whether they now posses liver cancer. If affirmative, the Kanzius Noninvasive Radiowave Cancer Treatment will be administered, allowing data to be collected and analyzed. The success of these tests is mandatory to move forward in approaching the FDA and ultimately advancing to human trials.
This month is one of the most exciting of 2013 for the Kanzius Foundation as the treatment begins this final round of testing before human involvement. While this final round of testing has no timetable and no immediate completion date, we are now closer than ever to bringing the Kanzius Noninvasive Radiowave Cancer Treatment to our loved ones. We are closer than ever to eradicating the unknown.
The commencement of the new “Million Dollar Challenge” was announced along with the latest research developments on May 10th. This was initiated by a generous, anonymous couple who wanted to ignite a spark among our followers. They have agreed to match $2 for every dollar donated to the Kanzius Foundation. Already, more than $75,000 has been donated making their match an additional $150,000! Kanzius Foundation followers have shown that they believe that “a better way” is near. The incredible response we have received further demonstrates that we can reach our million dollar goal and fund Dr. Curley’s research, helping to advance it to the FDA.
MARK A. NEIDIG SR. is executive director of the Kanzius Cancer Research Foundation (MNeidig@Kanzius.org).